Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin D for Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all sickle cell genotypes including SS, SB0thal, SC, SB+Thal~* Age 7-21 years old~* Last PRBC transfusion \>30 days prior~Exclusion Criteria:~* chronic renal failure~* chronic liver disease~* recent hospitalization \<14 days~* history of malignancy~* serum calcium level as defined in protocol section D 2.2~* treatment with concommitant medications as defined in section D 2.2 of the protocol~* known malabsorption or short gut syndrome or conditions associated with poor GI absorption~* patients currently on high dose vitamin D therapy

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): 10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
- Placebo (Type: PLACEBO_COMPARATOR): placebo only, all patients will receive calcium/vitamin D chew

Based on this trial design, predict the completion outcome and termination type (if applicable).